What SEC filings does Candel Therapeutics, Inc. submit to the SEC?

Candel Therapeutics, Inc. (CADL) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CADL?

A Form 4 for CADL discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Candel Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CADL?

The 10-K is Candel Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CADL SEC filings directly on EDGAR?

You can view all historical Candel Therapeutics, Inc. filings on the SEC EDGAR company page for CADL. Each filing card on this page links directly to the original SEC document.

How often does Candel Therapeutics, Inc. file with the SEC?

Candel Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CADL shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CADL SEC Filing News — Candel Therapeutics, Inc.

Latest SEC filings for Candel Therapeutics, Inc. (CADL) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,…

Sector: Healthcare Industry: Biotechnology Market Cap: $622.9M CIK: 1841387

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CADL currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

CADL Filing Activity Snapshot 2026-06-29 — 2026-10-02

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$3.41M

PAUL PETER TAK · 2026-09-10

280,245 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Candel Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 8 compensation award and 4 open-market sale. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×8: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

CADL insider Form 4 filed for equity award, exercise, or tax withholding

Loggia Nicoletta (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	380	$8.68	$3.3K

Filing: Form 4 (Insider Transaction) Insider: Loggia Nicoletta (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

CADL insider Form 4 filed for equity award, exercise, or tax withholding

PAPA JOSEPH C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	1,325	$8.68	$11.5K

Filing: Form 4 (Insider Transaction) Insider: PAPA JOSEPH C (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

CADL insider Form 4 filed for equity award, exercise, or tax withholding

Manning Paul B (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,189	$8.68	$19.0K

Filing: Form 4 (Insider Transaction) Insider: Manning Paul B (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-11

CADL insider Tak Paul Peter (Director, Chief Executive Officer) sold 280,245 shares (~$3.16M)

Tak Paul Peter, listed as Director, Chief Executive Officer at Candel Therapeutics, Inc., reported an open-market sale of 280,245 CADL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	125,000	$1.55	$193.8K
`S`	Open-market sale	220,866	$11.50	$2.54M
`S`	Open-market sale	59,379	$10.46	$620.9K
`M`	Option exercise derivative · Stock Option (Right to Buy)	125,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Tak Paul Peter (Director, Chief Executive Officer) Shares: 280,245 Est. Value: $3.16M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-10

CADL insider Form 4 filed for equity award, exercise, or tax withholding

Zimmermann Martine (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	64,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Zimmermann Martine (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-19

CADL insider Tyagarajan Seshu (Chief Technology Officer) sold 7,000 shares (~$84.0K)

Tyagarajan Seshu, listed as Chief Technology Officer at Candel Therapeutics, Inc., reported an open-market sale of 7,000 CADL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	7,000	$12.00	$84.0K

Filing: Form 4 (Insider Transaction) Insider: Tyagarajan Seshu (Chief Technology Officer) Shares: 7,000 Est. Value: $84.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-08

CADL insider Form 4 filed for equity award, exercise, or tax withholding

Sims Mark E. (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	285,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Sims Mark E. (Chief Commercial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-01

CADL insider Barone Francesca (Chief Scientific Officer) sold 23,447 shares (~$235.8K)

Barone Francesca, listed as Chief Scientific Officer at Candel Therapeutics, Inc., reported an open-market sale of 23,447 CADL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	23,447	$10.06	$235.8K

Filing: Form 4 (Insider Transaction) Insider: Barone Francesca (Chief Scientific Officer) Shares: 23,447 Est. Value: $235.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-01

CADL insider Tyagarajan Seshu (Chief Technology Officer) sold 7,000 shares (~$70.2K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	7,000	$10.02	$70.2K

Filing: Form 4 (Insider Transaction) Insider: Tyagarajan Seshu (Chief Technology Officer) Shares: 7,000 Est. Value: $70.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-01

CADL insider Form 4 filed for equity award, exercise, or tax withholding

Manning Paul B (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,199	$8.64	$19.0K

Filing: Form 4 (Insider Transaction) Insider: Manning Paul B (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-01

CADL insider Form 4 filed for equity award, exercise, or tax withholding

PAPA JOSEPH C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	1,331	$8.64	$11.5K

Filing: Form 4 (Insider Transaction) Insider: PAPA JOSEPH C (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-01

CADL insider Form 4 filed for equity award, exercise, or tax withholding

Loggia Nicoletta (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	381	$8.64	$3.3K

Filing: Form 4 (Insider Transaction) Insider: Loggia Nicoletta (Director)

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Candel Therapeutics, Inc. has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-10

CADL Form 144 filed for proposed insider sale by PAUL PETER TAK (280,245 shares) ~$3.41M

PAUL PETER TAK filed a Form 144 with the SEC indicating intent to sell CADL (Candel Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PAUL PETER TAK Shares: 280,245 Est. Value: $3.41M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-17

CADL Form 144 filed for proposed insider sale by SESHU TYAGARAJAN (7,000 shares) ~$82.0K

SESHU TYAGARAJAN filed a Form 144 with the SEC indicating intent to sell CADL (Candel Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SESHU TYAGARAJAN Shares: 7,000 Est. Value: $82.0K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-29

CADL Form 144 filed for proposed insider sale by SESHU P TYAGARAJAN (7,000 shares) ~$68.5K

SESHU P TYAGARAJAN filed a Form 144 with the SEC indicating intent to sell CADL (Candel Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SESHU P TYAGARAJAN Shares: 7,000 Est. Value: $68.5K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-29

CADL Form 144 filed for proposed insider sale by FRANCESCA BARONE (23,447 shares) ~$229.5K

FRANCESCA BARONE filed a Form 144 with the SEC indicating intent to sell CADL (Candel Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: FRANCESCA BARONE Shares: 23,447 Est. Value: $229.5K

View on SEC EDGAR → Open Filing Document →

Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Candel Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-10

CADL filed 8-K — material company event

Candel Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-09

CADL filed 8-K — material company event

Candel Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-13

CADL filed 8-K — material company event

Candel Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Candel Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-13

CADL filed Quarterly Report (10-Q)

Candel Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Candel Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CADL. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CADL SEC Filings

More Tools for CADL

CADL Full Stock Analysis CADL Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CADL analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CADL stock analysis page.

CADL Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer